Is Gilead Sciences Inc (GILD) overvalued? · P/E 18, rev $29.44B
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
This page asks whether Gilead Sciences Inc (GILD) looks expensive on cached numbers — not a short thesis.
Latest reported GILD revenue for 2025-12-31 was $29.44B. Net income was $8.51B. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next GILD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the GILD stock page for the full model, not this heading.
Not investment advice.